

## Suvizumab

<b>Cat. No.:</b>	HY-P99584
<b>CAS No.:</b>	914257-21-9
<b>Target:</b>	HIV
<b>Pathway:</b>	Anti-infection
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1 <sub>MN</sub> , HIV-1 <sub>SF2</sub> and HIV-1 <sub>89.6</sub> with IC <sub>50</sub> values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection <sup>[1][2]</sup> .			
<b>IC<sub>50</sub> &amp; Target</b>	HIV-1	HIV-1 <sub>89.6</sub> 0.2 µg/mL (IC <sub>50</sub> )	HIV-1 <sub>MN</sub> 0.1 µg/mL (IC <sub>50</sub> )	HIV-1 <sub>SF2</sub> 1.0 µg/mL (IC <sub>50</sub> )
<b>In Vitro</b>	Suvizumab shows highly resistant to pseudotyped virus with the G314E mutation <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
<b>In Vivo</b>	Suvizumab (15, 30 and 45 mg/kg; i.v.; single dose) attenuates viral attack and plasma viremia, and increased the number of CD4 <sup>+</sup> T cells in SHIV C2/1 infected cynomolgus monkeys with dose-dependent manner <sup>[2]</sup> . Suvizumab (45 mg/kg; i.v.; once a week for 2 months) reduces the loss of CD4 T cells in lymphoid tissue in male cynomolgus monkeys infected with simian/human immunodeficiency virus-C2/1 <sup>[4]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

### REFERENCES

- [1]. Matsushita S, et al. Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1. *AIDS*. 2015 Feb 20;29(4):453-62.
- [2]. Eda Y, et al. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. *J Virol*. 2006 Jun;80(11):5563-70.
- [3]. Yoshimura K, et al. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. *AIDS*. 2006 Oct 24;20(16):2065-73.
- [4]. Murakami T, et al. Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4<sup>+</sup> T-cell loss in macaque lymphoid tissue. *AIDS*. 2009 Jul 31;23(12):1485-94.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA